T ranscatheter aortic valve implantation (TAVI) has become the treatment of choice for patients with aortic stenosis who are considered to be nonoperable and a good alternative for those at high surgical risk.
studies with limited (≤1 year) follow-up. [8] [9] [10] [11] Although these studies did not find any impact of PPI on mortality, concerns that they may have been underpowered as a result of inadequate sample size have been raised. 12 In addition, no studies to date have evaluated the impact of PPI on rehospitalizations resulting from heart failure, left ventricular function changes, and sudden death. Finally, the vast majority of patients included in studies evaluating the impact of PPI after TAVI had received a SEV, [8] [9] [10] [11] and very few data exist on patients who received a BEV. Therefore, the aims of this study were to assess in a large cohort of patients undergoing TAVI with BEV and SEV the impact of new PPI on late outcomes (including mortality and rehospitalization for heart failure) and left ventricular function and functional status changes after the intervention.
Methods

Study Population
A total of 1811 consecutive patients who underwent TAVI with either a BEV or an SEV in 8 centers between January 2005 and February 2013 were screened. Of these, 233 patients were excluded because of preexisting pacemaker implantation and 22 patients because of an unsuccessful procedure without valve implantation. The final study population consisted of 1556 patients (BEV, 858 patients; SEV, 698 patients).
Patients were considered candidates for TAVI if they were at high or prohibitive predicted perioperative risk as evaluated by a heart team composed of cardiac surgeons and interventional cardiologists at each center. TAVI procedures were performed as previously described. 1 The study was conducted in accordance with the institutional ethics committee of each participating center, and all patients provided signed informed consent for the procedures. Data were collected prospectively in each center. Procedural complications for the purpose of this study were defined according to Valve Academic Research Consortium-2 criteria. 13 
Indications for PPI
In agreement with the American College of Cardiology/American Heart Association/Heart Rhythm Society recommendations, PPI was indicated if third-degree or advanced second-degree atrioventricular block (AVB) at any anatomic level occurred and was not expected to resolve or in the presence of sinus node dysfunction and documented symptomatic bradycardia. 14 The indication of PPI in the presence of left bundle-branch block (LBBB) with PR prolongation (>200 milliseconds) not expected to normalize was at the discretion of the physician. The selection of a single-chamber or dual-chamber pacemaker was left to the implanter.
Follow-Up
Follow-up was carried out through clinical outpatient visits or phone contacts at 30 days, 6 months, and 12 months and yearly afterward. No patient was lost during the follow-up period. Echocardiographic examinations at baseline were available in all patients, in 1279 patients at hospital discharge, and in 902 patients at the 6-to 12-month follow-up (83% of patients alive at that point of time, 89% and 78% in the BEV and SEV groups, respectively; P=0.002). Left ventricular ejection fraction (LVEF) was calculated from the biplane modified Simpson method, and left ventricular dysfunction was defined as LVEF ≤50%.
15
End Points and Definitions
The primary end point was defined as a composite of all-cause mortality and hospitalization resulting from heart failure at last follow-up. Secondary end points were all cause-mortality, cardiovascular mortality, sudden cardiac death, composite of sudden cardiac death and death resulting from an unknown cause, rehospitalization for heart failure, functional class changes, and LVEF changes. Several sources of information were used to investigate end points: outpatient clinical visits; phone contacts with patients, families, or physicians; and review of medical records to determine causes of death when necessary. All events were defined according to the Valve Academic Research Consortium-2 criteria. 13 Sudden cardiac death was defined as any unexpected death caused by cardiac disease occurring within 1 hour after of the onset of symptoms. 16 Death was classified as resulting from an unknown cause if the unexpected death failed to meet the confirmation criteria of sudden cardiac death and the cause of death could not be determined after contact with the responsible physician or the patient's family. Death resulting from an unknown cause was classified as cardiovascular death. 13 Only readmissions with a primary diagnosis of heart failure at hospital discharge were considered as rehospitalizations resulting from heart failure. For patients with several hospitalizations resulting from heart failure, only the first episode was included in the analysis.
Statistical Analysis
Qualitative variables are expressed as percentages and quantitative variables as mean±SD or median (interquartile range) according to variable distribution and were compared by use of the χ 2 or Fisher exact test and 2-sided t test or Wilcoxon signed-rank test as appropriate. The primary composite end point and secondary end points were compared between the PPI and no PPI and the BEV and SEV groups with the use of proportional hazard models (cumulative outcomes). All multivariate models were adjusted for baseline differences in the univariate analysis including variables with a value of P≤0.10. A landmark analysis with a landmark cutoff at 30 days was used to further investigate the impact of PPI on study outcomes. Thirty-day outcomes were assessed with a logistic regression model. Survival rates were summarized by use of Kaplan-Meier estimates, and the log-rank test was used for comparison between groups. A linear general model for repeated measures with interaction was used to compare the changes in LVEF at different time points between the PPI and no PPI groups. Further comparisons were performed with the Tukey technique. Predictors of LVEF changes over time were analyzed by use of a univariate and a multivariate linear regression model. The results were considered significant at values of P<0.05. Analyses were conducted with the statistical package SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
A total of 239 patients (15.4%) received a PPI within 30 days after TAVI (25.5% versus 7.1% in the SEV and BEV groups, respectively; P<0.001). Baseline and procedural characteristics of the study population according to the need for PPI after TAVI are shown in Table 1 . The timing, clinical indications, and pacemaker models implanted overall and according to the type of transcatheter valve (SEV or BEV) are shown in Table 2 . The 30-day outcomes according to study group (PPI versus no PPI) are shown in Table 3 . There were no differences between groups in 30-day mortality or major complications after TAVI (P>0.20 for all).
A resting ECG was performed at the 6-to 12-month follow-up in 133 patients with 30-day PPI (62% of patients at risk, 61.7% and 62.5% in the SEV and BEV groups, respectively; P=0.707) with the aim of assessing the presence of pacemaker activity. Pace rhythm was observed in 89 of these patients (66.9%), and it was more frequent in patients who had received an SEV (72.8% versus 46.7% in patients with a BEV; P=0.007).
30-Day PPI and Late Outcomes
Cumulative late clinical events grouped according to the need for PPI within 30 days after TAVI are shown in Table 4 . After by guest on November 11, 2017 http://circ.ahajournals.org/ Downloaded from a mean follow-up of 22±17 months, a total of 525 patients (33.7%) either had died or required a rehospitalization for heart failure, with no differences between the PPI and no PPI groups (34.1% versus 31.8%; hazard ratio [HR], 1.00; 95% confidence interval [CI] , 0.77-1.30; P=0.980). There were no differences between groups in the secondary end points of late overall and cardiovascular mortality or rehospitalization for heart failure ( Table 4 ). There was, however, a lower rate of unexpected (sudden or unknown) death among patients who had a PPI within 30 days after TAVI (HR, 0.31; 95% CI, 0.11-0.85; P=0.023). This protective effect of 30-day PPI on unexpected death persisted after a landmark analysis with a cutoff at 30 days (Table 4) .
The Kaplan-Meier curves at the 3-year follow-up according to the study group (PPI versus no PPI) are shown in Figure 1 .
The individual characteristics of the 76 patients who suffered sudden or unknown death are detailed in Table I in the online-only Data Supplement. Clinical, echocardiographic, and ECG univariate and multivariate predictors of unexpected (sudden and unknown) death and sudden cardiac death in the study population are shown in Table 5 . New-onset persistent LBBB (NOP-LBBB) was observed in 269 patients 
Subgroups Analyses (Low LVEF, Transcatheter Valve Type)
Late outcomes according to the need for PPI after TAVI in patients with low (≤50%) and normal (>50%) LVEF at baseline are shown in Table 6 . There were no differences in all-cause mortality and rehospitalization for heart failure, all-cause mortality, cardiovascular mortality, and sudden cardiac death between patients with and without LVEF ≤50% (P>0.10 for all). However, a higher rate of unexpected (sudden or unknown) death was observed in patients with no PPI and normal left ventricular function (P=0.043). In addition, no negative impact of PPI was encountered in patients with at least moderate left ventricular dysfunction (LVEF ≤40%; P>0.10 for all), with a protective effect on unexpected death in patients with normal or mildly depressed left ventricular function (P=0.023).
Baseline clinical characteristics and procedural findings and clinical outcomes during the follow-up period according to the type of valve implanted are given in Tables II and III in the online-only Data Supplement, respectively. Death or heart failure, death resulting from any cause and from cardiovascular causes, sudden cardiac death, sudden/unknown death, and hospitalizations for heart failure were similar in the SEV and BEV groups (P>0.10 for all).
The late outcomes according to the need for PPI after TAVI for the patients who had received a BEV or an SEV are shown in Table 7 . There were no differences in any of the late outcomes between patients with and without PPI in each of the transcatheter valve type groups. In the SEV group, a trend toward a lower rate of sudden cardiac/unknown death was observed in patients with PPI (HR, 0.30; 95% CI, 0.09-1.02; P=0.053). In the BEV group, the risk of sudden cardiac/ unknown death was similar in patients with and without PPI (HR, 0.28; 95% CI, 0.04-2.05; P=0.212). However, no significant interaction was found between the need of PPI and the type of valve implanted for unexpected death (P=0.997) and sudden cardiac death (P=0.984).
PPI, LVEF, and Functional Status
Changes in valve hemodynamics according to the need for PPI are shown in Figure I in the online-only Data Supplement. LVEF significantly increased in the overall population at 6-to 12-month follow-up (from 56±13% Figure 2A . Whereas LVEF increased over time in patients with no PPI, LVEF decreased at follow-up in those patients who had PPI after TAVI (P=0.017 for comparison between groups), without differences between the BEV and SEV groups (P=0.668; Figure 3 . A marked improvement in New York Heart Association class was observed in patients with and without 30-day PPI (P<0.001 for both groups) without differences in New York Heart Association class changes between the PPI and no PPI groups (P=0.672).
Discussion
Injury to the conduction system is one of the more frequent complications of TAVI. 17 Although there is wide variability in the incidence of pacing requirements across studies, 17 an analysis of the literature showed that 1 of 7 patients (<10% and up to ≈25% when using BEV and SEV, respectively) require a PPI periprocedurally, 18 which is consistent with the results of the present study. Also in accordance with prior studies, 18 almost 90% of PPIs at 30 days were implanted within the first week after the procedure, with a much lower risk thereafter, and 75% were secondary to high-degree or complete AVB.
PPI After TAVI and Clinical Outcomes
There is strong evidence that the need for a paced rhythm increases the risk of late mortality and heart failure. [2] [3] [4] [19] [20] [21] In contrast to these results, we failed to find any deleterious effect of PPI on mortality or heart failure status in patients undergoing TAVI, even in patients with left ventricular dysfunction at baseline. However, these finding are consistent with prior studies in the cardiac surgery field, 22 as well as with some prior smaller TAVI series. [8] [9] [10] [11] Results from the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial, Mode Selection Trial (MOST), and Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) showed that the deleterious impact of pacing on heart failure or mortality depends on cumulative percent time of ventricular pacing. Specifically, a right ventricular pacing during ≥40% to 50% of the time was associated with increased risk of heart failure or mortality. 2, 3, 23 Several studies on TAVI have shown that new conduction disturbances after TAVI may resolve over time in ≈50% of patients, 24, 25 especially with the use of BEV. Indeed, it has been shown that >50% of patients requiring periprocedural PPI are not pacing dependent at follow-up. 8, 26, 27 In the present study, more than one third of patients with PPI (>50% in patients who had received a BEV) did not exhibit pacing activity on the ECG performed at the 6-to 12-month followup. Because most PPIs were implanted as a result of a high degree of or complete AVB, this observation suggests that a significant proportion of AVBs have resolved over time. This is consistent with the situation observed after surgical aortic valve replacement, 28, 29 and in fact, current surgical guidelines recommend the implantation of a permanent pacemaker in patients with postoperative AVB only if the conduction abnormality persists at least 7 days after cardiac surgery or is not expected to resolve.
14 Interestingly, Simms It has been suggested that the deleterious impact of PPI might differ between younger and older patients 30 ; whereas a poorer survival has been observed in younger patients requiring PPI, some studies have shown that PPI has no impact on mortality in octogenarians and nonagenarians, 31 who in fact represent the vast majority of patients undergoing TAVI nowadays. In addition, the presence of left ventricular dysfunction has been reported as an independent predictor of a deleterious clinical impact of PPI, 32,33 whereas LVEF remained stable over time in most patients without structural heart disease receiving a PPI. 34 However, we did not find differences between patients with and without PPI when analyzing the data by subgroups according to left ventricular function. The severity of comorbidities and concomitant structural heart disease in patients undergoing TAVI led to a high rate of death and heart failure, and this might mitigate the potential negative effect of PPI in these patients.
Furthermore, the immediate hemodynamic improvement attributable to aortic stenosis release resulted in significant improvement of left ventricular function in patients with preexisting ventricular dysfunction (36±8% to 50±13%; P≤0.001), as previously reported, 35 and this may have compensated for the potential deleterious effect of ventricular pacing in such patients.
The fact that PPI after TAVI resulted in a significant decrease in unexpected (sudden cardiac and unknown) death during the follow-up period merits further evaluation. Preexisting atrial fibrillation and the lack of 30-day PPI were predictors of unexpected death, and the occurrence of NOP-LBBB and a lower LVEF at baseline predicted the occurrence of sudden death. Left ventricular dysfunction and atrial fibrillation are well-recognized predictors of sudden death, 36, 37 and NOP-LBBB after TAVI has been associated with an increased risk of late overall and cardiac mortality, 38 although this has not been confirmed in other studies. 24, 25 In this study, the occurrence of NOP-LBBB was not associated with overall or cardiac death, but it increased by >2 times the risk of sudden death during the follow-up period. NOP-LBBB after TAVI has been associated with a higher risk of PPI and complete AVB, 24 which in turn, might lead to sudden death if a pacemaker is not implanted. However, the number of sudden death events in the present study was relatively low; therefore, these results need to be interpreted with caution. Future studies are needed to assess the impact of NOP-LBBB after TAVI on sudden death and to evaluate the potential predictors of increased death in these patients.
PPI and LVEF
After an initial improvement in LVEF immediately after valve obstruction relief, those patients who required PPI exhibited a significant decrease in LVEF over time compared with a continuous improvement in ventricular function in the rest of the study population. In fact, PPI was the only factor determining a deleterious effect on ventricular function after TAVI. Importantly, this negative effect of PPI was more pronounced in those patients receiving a dual-chamber (versus single-chamber) PPI. It is well known that pacing induces electric and mechanical dyssynchrony, which in turn, may lead to an adverse left ventricular remodeling and ultimately to the development of heart failure. 7, 39, 40 The occurrence and extent of pacing-induced heart disease have been associated with ventricular pacing burden and duration, 33 and dual-chamber pacemakers have been associated with a higher percentage of cumulative pacing, leading to a higher risk of rehospitalization for heart failure. 3, 7 Interestingly, the implantation of a biventricular pacemaker in patients with preserved LVEF and symptomatic bradycardia and in those with AVB and left ventricular dysfunction has been shown to prevent the adverse effects of pacing on LVEF. 40, 41 The potential usefulness of biventricular pacing in patients requiring PPI after a TAVI procedure should be evaluated in future studies.
The negative impact of PPI on LVEF did not translate into a deleterious effect on the heart failure status, which may be related to the mild degree of LVEF deterioration in most 
Limitations
Although data were collected prospectively in each center, data analyses were performed retrospectively, and there was no event adjudication committee for the study. Echocardiographic examinations at follow-up were not completed in ≈15% of patients, and this may have had an impact on the results concerning LVEF changes over time. Pacing dependency and right ventricular pacing burden were not systematically evaluated. Finally, a bias cannot be ruled out in a comparison of outcomes between the BEV and SEV groups because of the lack of randomization.
Conclusions
This study including a large cohort of patients undergoing TAVI with BEV and SEV showed that periprocedural PPI remains a frequent complication of TAVI. The need for PPI periprocedurally had no impact on overall and cardiovascular death or on functional status and heart failure decompensation requiring rehospitalization after a mean follow-up of ≈2 years. Indeed, 30-day PPI was a protective factor for the occurrence of unexpected (sudden cardiac or unknown) death during the follow-up period, which indirectly raises questions about the most appropriate management of new conduction disturbances that do not meet the criteria for PPI after TAVI. However, PPI, particularly with a dual-chamber pacemaker, was associated with a negative effect on left ventricular function. Further efforts will be important to determine the long-term impact of this decrease in LVEF and the potential benefits of resynchronization therapies in some patients.
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